Quick Answer
Aquestive Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $31.81 million for the year ending 2020.
- Aquestive Therapeutics, Inc. showed a decrease of -35.5% in Cash And Cash Equivalents At Carrying Value from 2019 to 2020.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2021.
- XBRL data for this metric is available from 2016 to 2020 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $10.29 million | Q3 2017: $25.44 million | Q2 2018: $10.64 million | Q3 2018: $63.98 million | Q1 2019: $39.93 million | Q2 2019: $22.17 million | Q3 2019: $20.91 million | Q1 2020: $35.52 million | Q2 2020: $25.42 million | Q3 2020: $17.06 million | Q4 2020: $31.81 million | Q1 2021: $27.50 million | Q2 2021: $34.23 million | Q3 2021: $31.16 million | Q4 2021: $28.02 million | Q1 2022: $14.74 million | Q2 2022: $17.70 million | Q3 2022: $18.65 million | Q4 2022: $27.27 million | Q1 2023: $26.88 million | Q2 2023: $22.44 million | Q3 2023: $24.92 million | Q4 2023: $23.87 million | Q1 2024: $95.20 million | Q2 2024: $89.87 million | Q3 2024: $77.89 million | Q4 2024: $71.55 million | Q1 2025: $68.66 million | Q2 2025: $60.54 million | Q3 2025: $129.06 million.
- Over the full 5 years of available data (2016 to 2020), Aquestive Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 245.4%.
- Historical annual values: Fiscal year 2020: $31.81 million | Fiscal year 2019: $49.33 million | Fiscal year 2018: $60.60 million | Fiscal year 2017: $17.38 million | Fiscal year 2016: $9.21 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: